Pharmaceuticals Market Research Reports & Industry Analysis
Filter your search
Research Assistance
Pharmaceuticals Industry Research & Market Reports
-
Asia Pacific Intrauterine Contraceptive Device Market Forecast 2017-2025
...generating $1832 million over the forecast period of 2017-2025. MARKET INSIGHTS The market is segmented by type and by product. Presently, the copper IUCD market holds a major share of the market. The market is ... Read More
-
North America Intrauterine Contraceptive Device Market Forecast 2017-2025
...forecast period of 2017-2025 at a CAGR of 3.37%, generating $1156 million by the end of 2025. MARKET INSIGHTS The market is being presented with opportunities like a high rate of unintended pregnancies, teen pregnancies, ... Read More
-
Global Intrauterine Contraceptive Market Forecast 2017-2025
...projected to expand at a CAGR of 3.75%, increasing its revenue from $ 3534 million in 2016 to $4886 million by 2025 over the forecast period of 2017-2025. The key factors favoring the use of ... Read More
-
Europe Intrauterine Contraceptive Device Market Forecast 2017-2025
...be attributed to the estimated rise in the market’s CAGR by 3.24% over the forecast period of 2017-2025. MARKET INSIGHTS According to the Guttmacher Institute, IUCD is an essential part of family planning in the ... Read More
-
2018 U.S. Pharmaceutical Preparation Mfg.. Industry-Industry & Market Report
...the size of the industry (sales, establishments, employment) nationally and for all 50 U.S. States and over 900 metro areas. Other data include financial ratios, number of firms, payroll, industry definition, 5-year historical trends on ... Read More
-
2018 U.S. Psychiatric & Substance Abuse Hospitals Industry-Industry & Market Report
...estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S. States and over 900 metro areas. Other data include financial ratios, number of firms, payroll, industry definition, 5-year historical ... Read More
-
Bangladesh Pharmaceuticals and Healthcare Report Q4 2017
...Growing public healthcare spending and the government's efforts to improve the regulatory environmentwill be positive for the sector's development, although the large share of out-of-pocket spending as apercentage of health expenditure, as well as low ... Read More
-
Costa Rica Pharmaceuticals and Healthcare Report Q4 2017
...medical tourism destination and expandinghealthcare infrastructure that will need to cater to its gradually ageing population. However, the smallmarket size will continue to hamper its growth potential as well as its relative attractiveness. Headline Expenditure ... Read More
-
Pakistan Pharmaceuticals and Healthcare Report Q4 2017
...The unmet need for non-communicable disease treatments among low-income patients will createopportunities to provide affordable medicines. Headline Expenditure Projections Pharmaceuticals: PKR275.8bn (USD2.6bn) in 2016 to PRK301.2bn (USD2.9bn) 2017; +9.2% in localcurrency terms and +9.3% in ... Read More
-
Slovakia Pharmaceuticals and Healthcare Report Q4 2017
...this willpose fewer risks to drugmakers, Slovakia's market has less potential for growth than some of its similarlydevelopedregional neighbours, notably Poland. Headline Expenditure Projections Pharmaceuticals: EUR1.72bn (USD1.90bn) in 2016 to EUR1.80bn (USD1.98bn) in 2017; +4.7% ... Read More
-
Tunisia Pharmaceuticals and Healthcare Report Q4 2017
...a notable impact on developments within the pharmaceutical sector and wider economy;however, the actual benefits will take time to materialise. Crucially, higher growth opportunities willpresent themselves within the generic medicines sector, while the high industry-associated ... Read More
-
Ethiopia Pharmaceuticals and Healthcare Report Q4 2017
...Ethiopia remains a long way from achieving sustainable medicine production. Greaterinterest from foreign investors and further government support will boost the capacity of Ethiopia'spharmaceutical landscape over the long term; however, opportunities for patented firms will ... Read More
-
Nicaragua Pharmaceuticals and Healthcare Report Q4 2017
...of the overallmarket is among the smallest in Central America and is limited by a largely low-income population with astrong preference for traditional medicines. Furthermore, weak drug regulatory framework and poorhealthcare infrastructure will dampen multinational ... Read More
-
Philippines Pharmaceuticals and Healthcare Report Q4 2017
...the specific target of the 2017 budget is to expand healthcare access to low-income Filipinos. Moreover, the constraints on affordability and the demand for low-cost pharmaceuticals will spur greaterinvestment from drugmakers with strong generic drug ... Read More
-
Slovenia Pharmaceuticals and Healthcare Report Q4 2017
...of treatment quality and effectiveness. Inaddition, the healthcare system is experiencing rising debts to employees, which has been blamed oninefficient spending. Slovakia's pharmaceutical market, however, will remain one of the most attractive inCEE over the ... Read More
-
Heavy Metal Poisoning - Pipeline Review, H2 2017
...Poisoning (Toxicology) pipeline landscape. Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms ... Read More
-
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2017
...According to the recently published report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2017'; Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase ... Read More
-
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017
...to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017, outlays comprehensive ... Read More
-
Radiation Injury - Pipeline Review, H2 2017
...landscape. Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high ... Read More
-
Fallopian Tube Cancer - Pipeline Review, H2 2017
...Cancer (Oncology) pipeline landscape. Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common ... Read More
-
Chronic Urticaria Or Hives - Pipeline Review, H2 2017
...Chronic Urticaria Or Hives (Dermatology) pipeline landscape. Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of ... Read More
-
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2017
...9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the ... Read More
-
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
...of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types ... Read More
-
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017
...or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in ... Read More
-
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2017
...44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Superoxide Dismutase [Cu-Zn] - ... Read More
